Wechselwirkungen · Lojuxta
Lojuxta 2 mg hard capsules Lojuxta 5 mg hard capsules Lojuxta 10 mg hard capsules Lojuxta 20 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-127370 · Präparat HOS-096397
Inducers of Medicines that induce CYP3A4 When co-administering CYP3A4 inducers CYP3A4 would be expected to increase the (i.e. aminoglutethimide, nafcillin, rate and extent of metabolism of non-nucleoside reverse transcriptase lomitapide. Consequently, this inhibitors, phenobarbital, rifampicin, would reduce the effect of carbamazepine, pioglitazone, St John’s lomitapide. Any impact on efficacy Wort, glucocorticoids, modafinil and is likely to be variable. phenytoin) with Lojuxta, the possibility of a drug-drug interaction affecting efficacy should be considered. It is recommended to increase the frequency of LDL-C assessment during such concomitant use and consider increasing the dose of lomitapide to ensure maintenance of the desired level of efficacy if the CYP3A4 inducer is intended for chronic use.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) aminoglutethimide (HOS-127371) nafcillin (HOS-125452) pioglitazone (HOS-089663) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-25T14:24:00Z · SHA-256 56c36935b5cda4380e359902f1acbc5ec5bb081beeb96ca75e5ad86521fcd98c · Passage 50b645c2aa62dfce0afafbda5ce5ea0a9ce6e474f27e7abad1e68aec4b30839e · Zeichen 5862–7266 im Abschnitt